Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
      QxMD      Google Scholar   
Citation:
Br J Haematol vol 175 (2) 226-236
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Scientific Category: MYELOID NEOPLASIA
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
6
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
 
Grants:
P50 CA140158, U10 CA180861, U10 CA077658, U10 CA180821, U10 CA101140, U10 CA180882, U24 CA196171, P30 CA016058, U10 CA180867, R35 CA197734  
Corr. Author:
 
Authors:
                           
Networks:
LAPS-MA036, LAPS-OH007, NORTHWELL, OH070   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-20202, CALGB-10201, CALGB-10502, CALGB-10503, CALGB-10603, CALGB-19808, CALGB-9222, CALGB-9621, CALGB-9720
Phases:
1, 1/2, 2, 3, N/A
Keywords:
acute myeloid leukaemia, DNA (cytosine-5)-methyltransferase 3 alpha, mutation clearance, survival, prognosis